{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-016516","form_type":"8-K","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2026-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.897727+00:00","generated_at":"2026-05-15T15:45:08.341543+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"Vanda CEO reveals NEREUS launch plan: DTC channel, availability in months","bullets":["NEREUS approved by FDA for prevention of vomiting induced by motion sickness.","CEO disclosed development of direct-to-consumer channel NEREUSRX for NEREUS access.","NEREUS will be available in the next couple of months per CEO on Fox Business.","Pricing and commercial strategy for NEREUS discussed during interview."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-016516","json":"https://secwatch.observer/filing/0001628280-26-016516.json","markdown":"https://secwatch.observer/filing/0001628280-26-016516.md","text":"https://secwatch.observer/filing/0001628280-26-016516.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000162828026016516/0001628280-26-016516-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000162828026016516/vnda-20260310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T15:45:08.341543+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}